FDA Inspection Readiness
Former FDA investigators helping pharmaceutical, biotechnology, medical device, food, and cosmetics companies prepare for inspections, respond to FDA observations, and strengthen GMP compliance.
Step inside a regulated facility
Industry Universe
Explore cinematic walkthroughs of the facilities FDA investigators inspect. Each environment surfaces real risks, common 483 observations, and what investigators look for.
Pharmaceutical Manufacturing
From dispensing to packaging — every cGMP control under one roof.
Enter Environment
Biologics Manufacturing
Upstream, downstream, and aseptic fill — the biologics pressure points.
Enter Environment
Medical Device Manufacturing
Design controls, CAPA, and complaint handling under 21 CFR 820 / QMSR.
Enter Environment
Food Manufacturing
FSMA, allergen control, and environmental pathogen monitoring.
Enter Environment
Cosmetics Manufacturing
MoCRA compliance — adverse event reporting and facility registration.
Enter Environment
Compounding Pharmacy
USP <797>, <800>, and FDA 503B outsourcing facility expectations.
Enter Environment
QC Analytical Laboratory
HPLC, dissolution, stability, LIMS — and the data integrity that ties them together.
Enter Environment
Microbiology Laboratory
Sterility, endotoxin, EM — the sharp end of contamination control.
Enter Environment
Former FDA Investigators — Mock FDA Inspection Experts — FDA 483 Response Specialists
Why Choose Us
FDAInspections.com is powered by Global Regulatory Partners and led by former FDA investigators with decades of direct agency experience helping regulated companies achieve inspection readiness.
Core Services
Comprehensive regulatory consulting from investigators who’ve been on both sides of the FDA inspection process.
Realistic mock inspections conducted by former FDA investigators to identify vulnerabilities before the agency arrives.
Learn MoreSystematic evaluation of your quality systems against current FDA expectations and cGMP requirements.
Learn MoreStrategic response development to address inspectional observations and prevent escalation to warning letters.
Learn MoreExpert remediation planning and corrective action implementation to resolve FDA enforcement actions.
Learn MoreCore Services
Access curated FDA enforcement data and trend analysis to stay ahead of regulatory developments.
Searchable intelligence on FDA warning letters across industries, with trend analysis and compliance insights to benchmark your regulatory posture.
Explore DataDetailed analysis of FDA 483 observations by category, helping companies anticipate inspection focus areas and prepare targeted responses.
Explore DataAre the Result of Your Quality System.
learn
A comprehensive summary of FDA Form 483 inspectional observations, detailing top citation trends in drug and device manufacturing, root-cause investigation requirements, and actionable strategies for effective 15-day responses.
An executive summary analyzing the FDA Warning Letters published in July 2026. This review highlights CGMP breaches, quality unit failures, and crucial takeaways for life science quality management teams.
Navigating a targeted federal facility investigation demands a highly structured operational response strategy. This comprehensive technical guide analyzes exactly what occurs when investigators execute an unannounced FDA for cause inspection.…
Take Action
Don’t wait for a Form 483 or warning letter to take action. Our team of former FDA investigators will assess your readiness and build a tailored compliance strategy.
Common Questions
FDA inspection readiness is the state of preparedness a regulated company maintains to successfully undergo an FDA inspection at any time. It includes compliant quality systems, trained staff, complete documentation, and effective CAPA processes aligned with cGMP requirements.
An FDA Form 483 lists inspectional observations of conditions that may violate the Food, Drug, and Cosmetic Act. Companies should respond within 15 business days with specific corrective actions. Failure to address observations can escalate to warning letters or consent decrees.
Companies can prepare by conducting mock FDA inspections with former investigators, performing GMP gap analyses, ensuring documentation completeness, training staff on inspection protocols, and establishing robust deviation and CAPA management systems.
Yes. Mock inspections conducted by experienced former FDA investigators identify compliance gaps before the agency arrives, allowing companies to remediate weaknesses and build confidence in their quality systems.
Once your dates are confirmed, we provide secure payment options including card and online transfer. A deposit secures your booking, with the balance due closer to arrival. Full details are shared clearly before any payment is made.
Sign in to access member resources, inspection tools and training.
New here? Create an account
